López-Otero Avril, Ruiz-Delgado Guillermo J, Hernández-Arizpe Ana, Ruiz-Argüelles Alejandro, Ruiz-Argüelles Guillermo J
Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
Hematology. 2010 Dec;15(6):378-81. doi: 10.1179/102453310X12719010991669.
The flow-cytometric DNA content in the plasma cells of patients with multiple myeloma has been studied as a prognostic factor and contrasting results have been found. In a group of 45 patients with myeloma from a single institution, the DNA content of the malignant plasma cells was studied by means of flow cytometry: no patients were found to have hypodiploid DNA content, 14 patients had hyperdiploid DNA, and 31 patients were found to have diploid DNA. The overall survival of patients with hyperdiploid DNA was better than that of patients with diploid DNA: 93% at 85 months and 79% at 89 months, respectively; in both groups, the median overall survival has not been reached. No correlation was found between the DNA content and the International Staging System and the discriminatory effect of the DNA content was apparent only in the patients who were not autografted. It is concluded that the flow-cytometric DNA content of the plasma cells of patients with multiple myeloma may be a prognostic factor independent of others already identified and that myeloma patients with hyperdiploid DNA content in the plasma cells may have a better prognosis than those with a normal DNA content.
多发性骨髓瘤患者浆细胞的流式细胞术DNA含量已作为一项预后因素进行研究，结果存在差异。在一家机构的45例骨髓瘤患者中，通过流式细胞术研究恶性浆细胞的DNA含量：未发现患者有亚二倍体DNA含量，14例患者有超二倍体DNA，31例患者有二倍体DNA。超二倍体DNA患者的总生存率优于二倍体DNA患者：分别为85个月时93%和89个月时79%；两组均未达到中位总生存期。未发现DNA含量与国际分期系统之间存在相关性，且DNA含量的鉴别作用仅在未进行自体移植的患者中明显。结论是，多发性骨髓瘤患者浆细胞的流式细胞术DNA含量可能是一个独立于其他已确定因素的预后因素，且浆细胞中DNA含量为超二倍体的骨髓瘤患者的预后可能优于DNA含量正常的患者。
